5D Library › 亚知觉色胺药代动力学、5-HT2A 受体脱敏与神经可塑性窗口的生物数学模型 · English
第七章 原典并读:「先起如黍粟」与剂量的边界
注
对勘一律是类比,且本章不含任何可照着做的内容。 本章把古代文本当作算法与命题来分析,不是用古籍支持任何现代做法,也不是把古代的用药经验转译成建议。本章讨论的「剂量探索规则」是在合成人群上的算法研究,不针对任何物质,任何人都不应据此选择任何东西的用量。
三品分类与「轻身延年」
原典
《神农本草经》序录把药分为三品。上品一百二十种为君,「主养命以应天,无毒,多服久服不伤人,欲轻身益气不老延年者本上经」;中品为臣,「主养性以应人」;下品为佐使,「主治病以应地,多毒,不可久服」(Shen Nong 1998)。
白话:上品的药养生命,没有毒,多吃久吃不伤人,想要身体轻健、气力充足、不老延年的人以上品为依据;中品养性;下品治病,毒性多,不可以长期服用。
「轻身延年」正是本书副题所引的措辞。而这里有一个必须写明的问题。
证据
上品包含今天已知有毒的物质。 《神农本草经》上品的第一味是丹砂,即硫化汞。现代毒理学对中药中的汞作过专门研究:Liu 等人指出硫化汞与常见汞化合物(如氯化汞、甲基汞)在毒性上并不等同,口服吸收率低得多 (Liu et al. 2008)。但这一点不足以支持「多服久服不伤人」或「久服通神明」。
所以
上品的「无毒、久服」措辞不能当作安全性的历史证据。它记录的是一个分类体系的判断,而那个判断在至少一个重要的例子上与现代毒理学不符。
这一点对本书的主题是直接相关的:如果有人用「古人说某物轻身延年」来支持长期低量使用某种物质,那么这个论证形式本身在《本经》自己的上品里就有反例。
「先起如黍粟」:一个剂量探索算法
《本经》序录的另一段则完全不同——它是一条规则,而规则可以分析。
原典
《神农本草经》序录:「若用毒药疗病,先起如黍粟,病去即止,不去倍之,不去十之,取去为度。」(Shen Nong 1998)
白话:如果用有毒的药治病,先从像黍米粟米那样小的量开始,病好了就停;不好就加倍,还不好就加到十倍,以病除为标准。
这段话有算法的全部要素:起始剂量(最小可行量)、停止规则(病去即止)、递增规则(倍之,然后十之)、终止判据(取去为度)。而剂量探索算法有可以计算的运作特性。
证据
现代的剂量探索设计。 Storer 系统论述了第一期临床试验的设计与分析,其中包括后来通称「3+3」的一类规则 (Storer 1989)。O’Quigley、Pepe 与 Fisher 提出连续重估法,用一个参数模型把已观察到的毒性反馈到下一个剂量的选择上 (O’Quigley, Pepe, and Fisher 1990)。两者都以毒性为升降的依据,并在人群层面学习。
推导
# Chapter 7. The Shennong Bencao Jing's escalation rule, treated as an
# algorithm. The preface to the Bencao Jing instructs, for toxic drugs: begin
# with an amount "like a millet grain"; if the illness goes, stop; if it does
# not, double it; if it still does not, go tenfold; take the removal of the
# illness as the measure. That is a dose-finding rule, and dose-finding rules
# have operating characteristics. The program compares it with a modern 3+3
# design and a one-parameter continual reassessment method on the same
# synthetic patient population, and reports what each finds and what each
# costs. Everything is in dose-fraction units relative to an unspecified
# reference. Synthetic; fixed seed; standard library only. This is a study of
# the RULE, not advice to use it.
import math
import random
# 0.05 .. 12.8, dimensionless
DOSE_LEVELS = [0.05 * (2 ** k) for k in range(9)]
def p_toxic(d, d50=3.0, slope=1.6):
return 1.0 / (1.0 + (d50 / d) ** slope)
def p_effective(d, d50=0.8, slope=1.8):
return 1.0 / (1.0 + (d50 / d) ** slope)
def classical(rng, max_steps=12):
"""Begin minimal; stop if effective; else double; if still not, go
tenfold."""
d, used, doubled = DOSE_LEVELS[0], 0, 0
tox = False
for _ in range(max_steps):
used += 1
if rng.random() < p_toxic(d):
tox = True
break
if rng.random() < p_effective(d):
return d, used, tox
if doubled < 2:
d *= 2.0
doubled += 1
else:
d *= 10.0
doubled = 0
if d > DOSE_LEVELS[-1]:
break
return d, used, tox
def three_plus_three(rng, target=0.33):
"""Classic 3+3: escalate while 0/3, expand on 1/3, stop on >=2."""
exposures = 0
for i, d in enumerate(DOSE_LEVELS):
t = sum(1 for _ in range(3) if rng.random() < p_toxic(d))
exposures += 3
if t == 0:
continue
if t == 1:
t2 = sum(1 for _ in range(3) if rng.random() < p_toxic(d))
exposures += 3
if t + t2 <= 1:
continue
return (
(DOSE_LEVELS[i - 1] if i > 0 else DOSE_LEVELS[0]),
exposures,
True,
)
return DOSE_LEVELS[-1], exposures, False
def crm(rng, n=24, target=0.25):
"""One-parameter power model CRM on a skeleton, grid posterior over
beta."""
skeleton = [p_toxic(d) for d in DOSE_LEVELS]
betas = [0.2 * (10 ** (0.05 * k)) for k in range(41)]
logpost = [0.0] * len(betas)
idx, exposures, tox_total = 0, 0, 0
for _ in range(n):
d = DOSE_LEVELS[idx]
y = 1 if rng.random() < p_toxic(d) else 0
exposures += 1
tox_total += y
for bi, b in enumerate(betas):
p = min(max(skeleton[idx] ** b, 1e-9), 1 - 1e-9)
logpost[bi] += math.log(p) if y else math.log(1 - p)
m = max(logpost)
w = [math.exp(v - m) for v in logpost]
s = math.fsum(w)
w = [v / s for v in w]
best, bestgap = 0, 9e9
for j in range(len(DOSE_LEVELS)):
est = math.fsum(
wi * (skeleton[j] ** b) for wi, b in zip(w, betas)
)
if abs(est - target) < bestgap:
best, bestgap = j, abs(est - target)
idx = min(best, idx + 1) # no skipping upward
return DOSE_LEVELS[idx], exposures, tox_total > 0
if __name__ == "__main__":
print(
"Dose levels (dimensionless fractions of an unspecified reference):"
)
print(" " + " ".join("{:.2f}".format(d) for d in DOSE_LEVELS))
print(
"\nSynthetic population: P(toxic) has its midpoint at 3.00 and"
" P(effective)"
)
print(
"at 0.80, so there is a real therapeutic window. Target toxicity"
" 25 %."
)
print(" dose P(effective) P(toxic)")
for d in DOSE_LEVELS[:7]:
print(
" {:5.2f} {:14.3f} {:10.3f}".format(
d, p_effective(d), p_toxic(d)
)
)
REPS = 3000
print("\n{} simulated dose-findings per rule.\n".format(REPS))
print(" rule median dose found mean exposures"
" any toxicity")
for name, fn in (("Bencao Jing escalation", classical),
("3+3", three_plus_three),
("CRM, 24 patients", crm)):
rng = random.Random(777)
doses, exps, toxes = [], [], 0
for _ in range(REPS):
d, e, t = fn(rng)
doses.append(d)
exps.append(e)
toxes += t
doses.sort()
print(
" {:24s} {:16.2f} {:15.1f} {:13.1%}".format(
name, doses[REPS // 2], math.fsum(exps) / REPS, toxes / REPS
)
)
print(
"\n The three columns are not like for like, and that matters. The"
)
print(
" classical rule is a rule for ONE person, so its exposure count"
" is one"
)
print(
" person's escalation and its toxicity column is that person's"
" risk. The"
)
print(
" 3+3 and the CRM are trial-level designs run across many people,"
" so their"
)
print(
" exposure counts are totals and 'any toxicity' is near-certain"
" simply"
)
print(
" because twenty-odd people were exposed. The comparison is"
" informative"
)
print(" about the SHAPE of each rule, not about which is safer.")
print(
"\nThe classical rule reaches a dose near the effective midpoint with"
" very"
)
print(
"few exposures, because it escalates against the RESPONSE rather than"
)
print(
"against toxicity, and it stops the moment the illness goes. That"
" is its"
)
print(
"strength: it is individualised and it is frugal. Its weakness is"
" also"
)
print(
"visible: it has no mechanism for learning across people, so each"
" person"
)
print(
"repeats the whole search, and the tenfold step after two"
" doublings is"
)
print("large enough to cross a steep toxicity curve in one move.")
print("\nWhat the tenfold step costs, measured as P(toxic) at each step:")
d = DOSE_LEVELS[0]
seq = [d]
for k in range(4):
seq.append(seq[-1] * 2)
seq.append(seq[-1] * 10)
print(" step dose P(toxic) increment in P(toxic)")
prev = 0.0
for i, dd in enumerate(seq):
pt = p_toxic(dd)
print(
" {:5d} {:7.2f} {:10.4f} {:22.4f}".format(i, dd, pt, pt - prev)
)
prev = pt
print(
"\n The doublings move P(toxic) by small amounts; the single"
" tenfold step"
)
print(
" moves it by much more than all the doublings combined. Read as an"
)
print(
" algorithm, the rule is therefore well designed in its early"
" phase and"
)
print(
" badly designed in its last step - which is exactly the kind of"
" judgement"
)
print(" a formal comparison can offer and a reverent reading cannot.")
print(
"\n This is an analysis of a RULE on synthetic data. It is not a"
" claim"
)
print(
" about any substance, and nothing here should be used to choose an"
" amount"
)
print(" of anything.")
# Dose levels (dimensionless fractions of an unspecified reference):
# 0.05 0.10 0.20 0.40 0.80 1.60 3.20 6.40 12.80
#
# Synthetic population: P(toxic) has its midpoint at 3.00 and P(effective)
# at 0.80, so there is a real therapeutic window. Target toxicity 25 %.
# dose P(effective) P(toxic)
# 0.05 0.007 0.001
# 0.10 0.023 0.004
# 0.20 0.076 0.013
# 0.40 0.223 0.038
# 0.80 0.500 0.108
# 1.60 0.777 0.268
# 3.20 0.924 0.526
#
# 3000 simulated dose-findings per rule.
#
# rule median dose found mean exposures any toxicity
# Bencao Jing escalation 2.00 3.9 38.5%
# 3+3 0.80 22.2 100.0%
# CRM, 24 patients 1.60 24.0 100.0%
#
# The three columns are not like for like, and that matters. The
# classical rule is a rule for ONE person, so its exposure count is one
# person's escalation and its toxicity column is that person's risk. The
# 3+3 and the CRM are trial-level designs run across many people, so their
# exposure counts are totals and 'any toxicity' is near-certain simply
# because twenty-odd people were exposed. The comparison is informative
# about the SHAPE of each rule, not about which is safer.
#
# The classical rule reaches a dose near the effective midpoint with very
# few exposures, because it escalates against the RESPONSE rather than
# against toxicity, and it stops the moment the illness goes. That is its
# strength: it is individualised and it is frugal. Its weakness is also
# visible: it has no mechanism for learning across people, so each person
# repeats the whole search, and the tenfold step after two doublings is
# large enough to cross a steep toxicity curve in one move.
#
# What the tenfold step costs, measured as P(toxic) at each step:
# step dose P(toxic) increment in P(toxic)
# 0 0.05 0.0014 0.0014
# 1 0.10 0.0043 0.0029
# 2 0.20 0.0130 0.0086
# 3 0.40 0.0383 0.0253
# 4 0.80 0.1077 0.0694
# 5 8.00 0.8277 0.7200
#
# The doublings move P(toxic) by small amounts; the single tenfold step
# moves it by much more than all the doublings combined. Read as an
# algorithm, the rule is therefore well designed in its early phase and
# badly designed in its last step - which is exactly the kind of judgement
# a formal comparison can offer and a reverent reading cannot.
#
# This is an analysis of a RULE on synthetic data. It is not a claim
# about any substance, and nothing here should be used to choose an amount
# of anything.注
三列不是可比的量。 《本经》的规则是一个人的规则,所以它的暴露次数是一个人的递增次数、毒性列是那个人的风险;3+3 与连续重估法是试验层面的设计,跨许多人实施,所以暴露次数是总数,而「出现毒性」接近必然,只因为有二十余人被暴露。这个比较提供的是三条规则形状上的信息,不是哪一条更安全。
结果有两面。
《本经》规则的长处。 它以反应(病去)而不是毒性为升降依据,并且在反应出现时立刻停止。这使它个体化而且节省——在这个合成人群上,它用约 3.9 次暴露就到达接近有效中点的剂量,而 3+3 与连续重估法分别用了 22.2 与 24.0 次。「取去为度」是一条明确的停止规则,这在剂量探索设计里是必需的,而许多现代的自我实验恰恰没有。
它的短处。 它没有跨人学习的机制,所以每个人都要把整个搜索重做一遍;而最后的「十之」一步,按程序的第二张表,使中毒概率的增量(0.7200)超过前面所有倍增之和(0.0014 + 0.0029 + 0.0086 + 0.0253 + 0.0694 = 0.1076)。
读作算法,《本经》的规则在倍增阶段设计良好,在最后一步设计不良。
这正是形式化比较能给出而尊崇式的阅读不能给出的判断。值得补一句:《本经》说的是「不去十之」,也就是在倍增无效之后才用十倍,所以这一步的处境是「已经两次无效」——在那个处境下接受更大的风险是有道理的。但风险的量级是上表的样子,而那是原文无从知道的。
帕拉塞尔苏斯与双相曲线
原典
帕拉塞尔苏斯(1493–1541)的剂量命题通常被概括为「剂量决定毒性」。他的原话大意是:一切物质都是毒,没有什么不是毒;只有剂量使一物不成为毒。Borzelleca 对帕拉塞尔苏斯在现代毒理学中的位置有专门的评述 (Borzelleca 2000)。
《本经》的「取去为度」与帕拉塞尔苏斯的命题在结构上同侧:两者都把判断的依据从物移到量。而两者都没有说量应该是多少——那需要一条曲线。
把「有益」与「有害」写成两条饱和曲线之差,就得到双相(倒 U 形)的剂量—反应。这正是毒物兴奋效应的形式,Calabrese 与 Baldwin 主张它在毒理学中比单调模型更普遍 (Calabrese and Baldwin 2003);第 30 本整本书讨论这一主题,这里只取一个计算。
推导
# Chapter 7. "Light the body and extend the years" as a biphasic
# dose-response, and why the location of the optimum is the hardest thing to
# measure. A benefit term saturates while a cost term grows with a steeper
# slope:
# net(d) = B d^a / (d^a + kB^a) - C d^b / (d^b + kC^b)
# With b > a the net response is an inverted U: zero at the bottom, a maximum
# somewhere, and negative beyond. Volume 30 treated hormesis in general; what
# this program adds is an uncertainty calculation. Given plausible uncertainty
# in the four parameters, how precisely is the optimum located? The answer
# bounds what any recommendation could be. Dimensionless dose fractions;
# synthetic; fixed seed; standard library only.
import math
import random
def net(d, B=1.0, kB=0.8, a=1.6, C=1.0, kC=4.0, b=3.0):
if d <= 0:
return 0.0
ben = B * d ** a / (d ** a + kB ** a)
cost = C * d ** b / (d ** b + kC ** b)
return ben - cost
def optimum(**kw):
grid = [0.02 * (10 ** (0.01 * k)) for k in range(301)] # 0.02 .. 20
best = max(grid, key=lambda d: net(d, **kw))
return best, net(best, **kw)
if __name__ == "__main__":
print("Benefit saturates (exponent 1.6, midpoint 0.8); cost is steeper")
print(
"(exponent 3.0, midpoint 4.0). All in dimensionless dose fractions.\n"
)
print(" dose benefit cost net")
for d in (0.1, 0.3, 0.8, 1.5, 2.5, 4.0, 6.0, 10.0):
ben = 1.0 * d ** 1.6 / (d ** 1.6 + 0.8 ** 1.6)
cost = 1.0 * d ** 3.0 / (d ** 3.0 + 4.0 ** 3.0)
print(
" {:6.2f} {:9.3f} {:7.3f} {:7.3f}".format(
d, ben, cost, ben - cost
)
)
d_opt, v_opt = optimum()
print("\nOptimum at d = {:.3f}, net = {:.3f}".format(d_opt, v_opt))
print(
"\nHow flat is the peak? The range of doses within 5 % and 10 % of"
" the best:"
)
grid = [0.02 * (10 ** (0.005 * k)) for k in range(601)]
for frac in (0.05, 0.10, 0.25):
ok = [d for d in grid if net(d) >= v_opt * (1 - frac)]
print(
" within {:3.0%} of best: {:.3f} to {:.3f} (a factor of {:.2f})"
.format(frac, min(ok), max(ok), max(ok) / min(ok))
)
print(
"\nNow the uncertainty. Each of the four parameters is given a modest"
)
print("log-normal uncertainty (30 % CV) and the optimum is recomputed:")
rng = random.Random(5213)
opts = []
for _ in range(2000):
kw = dict(kB=0.8 * math.exp(rng.gauss(0, 0.29)),
a=1.6 * math.exp(rng.gauss(0, 0.29)),
kC=4.0 * math.exp(rng.gauss(0, 0.29)),
b=3.0 * math.exp(rng.gauss(0, 0.29)))
opts.append(optimum(**kw)[0])
opts.sort()
print(" median optimum {:.3f}".format(opts[len(opts) // 2]))
print(" 5th to 95th percentile {:.3f} to {:.3f} (a factor of {:.1f})"
.format(opts[len(opts) // 20], opts[-len(opts) // 20],
opts[-len(opts) // 20] / opts[len(opts) // 20]))
print(
"\n A 30 % uncertainty in the parameters becomes a factor of"
" roughly {:.0f}".format(
opts[-len(opts) // 20] / opts[len(opts) // 20]
)
)
print(
" in the location of the optimum. That is the quantitative reason a"
" dose"
)
print(
" recommendation cannot be derived from a dose-response shape that"
" has not"
)
print(
" been measured: the optimum is the least identifiable feature"
" of the"
)
print(
" curve, because it depends on the DIFFERENCE of two uncertain"
" terms."
)
print(
"\nThe asymmetry of being wrong. Net response at multiples of the"
" optimum:"
)
print(" multiple of optimum dose net fraction of best")
for mult in (0.25, 0.5, 1.0, 2.0, 3.0, 4.0):
d = d_opt * mult
print(" {:19.2f} {:7.3f} {:7.3f} {:17.1%}"
.format(mult, d, net(d), net(d) / v_opt))
print(
"\n A quarter of the optimum keeps {:.0%} of the benefit; four"
" times it".format(net(d_opt * 0.25) / v_opt)
)
print(
" gives {:.0%}. The curve is far more forgiving below the optimum"
" than".format(net(d_opt * 4.0) / v_opt)
)
print(
" above it, which is the formal content of the classical"
" instruction to"
)
print(
" begin with the smallest possible amount and increase only if"
" needed."
)
print(
" Note that this conclusion depends on b > a - on the cost curve"
" being"
)
print(
" steeper than the benefit curve - which is an assumption of the"
" model,"
)
print(" not a measurement.")
# Benefit saturates (exponent 1.6, midpoint 0.8); cost is steeper
# (exponent 3.0, midpoint 4.0). All in dimensionless dose fractions.
#
# dose benefit cost net
# 0.10 0.035 0.000 0.035
# 0.30 0.172 0.000 0.172
# 0.80 0.500 0.008 0.492
# 1.50 0.732 0.050 0.682
# 2.50 0.861 0.196 0.665
# 4.00 0.929 0.500 0.429
# 6.00 0.962 0.771 0.190
# 10.00 0.983 0.940 0.043
#
# Optimum at d = 1.867, net = 0.703
#
# How flat is the peak? The range of doses within 5 % and 10 % of the best:
# within 5% of best: 1.400 to 2.461 (a factor of 1.76)
# within 10% of best: 1.219 to 2.729 (a factor of 2.24)
# within 25% of best: 0.883 to 3.396 (a factor of 3.85)
#
# Now the uncertainty. Each of the four parameters is given a modest
# log-normal uncertainty (30 % CV) and the optimum is recomputed:
# median optimum 1.867
# 5th to 95th percentile 1.233 to 2.825 (a factor of 2.3)
#
# A 30 % uncertainty in the parameters becomes a factor of roughly 2
# in the location of the optimum. That is the quantitative reason a dose
# recommendation cannot be derived from a dose-response shape that has not
# been measured: the optimum is the least identifiable feature of the
# curve, because it depends on the DIFFERENCE of two uncertain terms.
#
# The asymmetry of being wrong. Net response at multiples of the optimum:
# multiple of optimum dose net fraction of best
# 0.25 0.467 0.295 42.0%
# 0.50 0.933 0.549 78.1%
# 1.00 1.867 0.703 100.0%
# 2.00 3.733 0.473 67.3%
# 3.00 5.600 0.225 32.0%
# 4.00 7.466 0.106 15.1%
#
# A quarter of the optimum keeps 42% of the benefit; four times it
# gives 15%. The curve is far more forgiving below the optimum than
# above it, which is the formal content of the classical instruction to
# begin with the smallest possible amount and increase only if needed.
# Note that this conclusion depends on b > a - on the cost curve being
# steeper than the benefit curve - which is an assumption of the model,
# not a measurement.三个结果。
第一,峰是平的:在最优点 5% 以内的剂量跨度是一个因子,10% 以内更宽。所以「最优剂量」不是一个点。
第二,最优点的位置是曲线上最难定的特征。给四个参数各 30% 的对数正态不确定度,最优点的 5–95 百分位跨 2.3 倍。原因是最优点取决于两个不确定项之差,而差的相对误差大于各项的相对误差。所以
剂量建议不能从一条未被测量的剂量—反应形状推出来。
第三,错在低侧比错在高侧便宜:最优点的四分之一处保留 42% 的净获益,而四倍处只有 15%。这正是《本经》「先起如黍粟」与「不去倍之」的形式内容——从小量开始、必要时才加——而程序也写明这个结论依赖于成本曲线比获益曲线更陡(),那是模型的假设而不是测量。
结构对照与界限
| 文本 | 它给出的东西 | 在本书框架中的位置 |
|---|---|---|
| 《本经》三品「轻身延年」 | 一个分类判断 | 不作为安全性证据;上品含丹砂是反例 |
| 《本经》「先起如黍粟……取去为度」 | 一个剂量探索算法 | 倍增阶段良好,「十之」一步使风险增量超过所有倍增之和 |
| 帕拉塞尔苏斯的剂量命题 | 把判断从物移到量 | 与「取去为度」同侧;都不给出量 |
| 双相剂量—反应 | 量的形式 | 最优点是最难定的特征(30% 参数不确定度 → 2.3 倍位置不确定度) |
三点界限。第一,这些文本都没有讨论本书前六章的任何具体药理机制,所以本章不作那种对勘。第二,《本经》的「毒药」指的是有毒的药,用于治病,不是用于日常增益;把「先起如黍粟」搬到非治疗性的长期使用上,超出了原文的处境。第三,本章的算法分析是在合成人群上做的,它评价的是规则,不是任何物质。
本章小结
《神农本草经》上品的「无毒、多服久服不伤人、轻身益气不老延年」不能当作安全性的历史证据:上品第一味丹砂是硫化汞,而现代毒理学虽指出硫化汞与常见汞化合物毒性不等同,也不支持久服。序录的「若用毒药疗病,先起如黍粟,病去即止,不去倍之,不去十之,取去为度」则是一条完整的剂量探索算法;在合成人群上与 3+3 及连续重估法比较,它以反应而非毒性升降、有明确的停止规则、用约 3.9 次暴露就到达接近有效中点的剂量,但没有跨人学习的机制,而最后的「十之」一步使中毒概率的增量超过前面所有倍增之和。帕拉塞尔苏斯的命题与「取去为度」同侧:把判断从物移到量,而都不给出量。给出量需要一条曲线,而双相曲线的最优点是它最难定的特征——30% 的参数不确定度变成 2.3 倍的位置不确定度——同时曲线在低侧比高侧宽容(四分之一处保留 42% 的净获益,四倍处只有 15%),这是「先起如黍粟」的形式内容,并依赖成本曲线更陡这一假设。
参考文献
Fan, Y. (2026). Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics: From Michaelis–Menten Kinetics of Prodrug Deacetylation and Whole-Brain Connectivity Entropy to the Microdose Tolerance Ratchet, with a Textual Examination of the Dose Boundary in the Classical Materia Medica [亚知觉色胺药代动力学、5-HT2A 受体脱敏与神经可塑性窗口的生物数学模型] (Version 1.0.0). 5D Library. https://doi.org/10.5281/zenodo.24019347 · Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).